Acute myeloid leukemia (AML) is a leading cause of cancer-related deaths in young adults and a highly lethal disease in older adults. Most AML patients do not survive longer than two years.

The Leucegene project will help pave the way for a new era in personalized medicine and offer patients better targeted therapies. We envision higher cure rates and longer, disease-free lifespans for AML patients.


Vincent Lavallée's Laboratory is joining the Leucegene group!

Vincent will bring his expertise in single cell sequencing analysis!…

The Cost-effectiveness analysis of HMGA2 prognostic test for AML is now published

Cost-effectiveness analysis of a HMGA2 prognostic test for acute…


Next-generation sequencing, chemogenomic and precision medicine approaches to cure AML

Health Care Providers

Driving new prognostic tests to the clinic through socio-economic studies and clinician engagement


Delivering precision medicine for AML to provide cures for this disease

Our Partners